Efeito protetor do ácido fítico em doenças cardiovasculares : revisão sistemática

• Ano de defesa: 2022
• Autor(a) principal: Pereira, Éverton Almeida
• Orientador(a): Santos, Sandra Lauton
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Programa de Pós-Graduação: Pós-Graduação em Ciências Fisiológicas
• Palavras-chave em Português: Doenças cardiovasculares; Ácido fítico; Calcificação; Doenças; Coração
• Palavras-chave em Inglês: Phytic acid; Illness; Heart; Calcification
• Área do conhecimento CNPq: CIENCIAS BIOLOGICAS::FISIOLOGIA
• Link de acesso: http://ri.ufs.br/jspui/handle/riufs/16324

Introduction: Cardiovascular diseases (CVDs) correspond to a set of diseases that affect the heart and blood vessels and are the main causes of death worldwide. Phytic acid, a dietary constituent normally found in foods such as seeds, has been linked to pharmacological properties such as anticancer, antioxidant, anti-inflammatory, anticalcifying and antidyslipidemic. Objective: To evaluate studies on the effects of phytic acid on cardiovascular diseases. Method: The protocol was registered in PROSPERO (CRD42022322188). The main question of the review was: “What is the effect of phytic acid on cardiovascular diseases?”. The research was carried out through search strategies in four databases, namely: Pubmed, ScienceDirect, Scopus and SciELO from November to December 2021, without the language or year of publication. We included preclinical and clinical in vivo trials with phytic acid management in the treatment of cardiovascular disease, which had the risks of bias analyzed using the Syrcle and Revman. Two researchers independently one examiner of the data, and the researcher responsible for analyzing the discrepancies. Results: Eleven studies were selected and confirmed. From these studies, we showed that phytic acid had a therapeutic effect on cardiovascular diseases such as ardiovascular calcification and myocardial ischemia, as well as we verified that experimental and clinical studies were carried out in rodents (rats and mice) and humans, in several research centers around the world, In addition to some preclinical articles, there was a predominance of uncertain risk of bias and for clinicians, the predominance was low risk of bias. Doses range from 0.825 μmol/kg to 600 mg/person, via oral, intravenous, subcutaneous and topical administration routes. Conclusions: Phytic acid causes beneficial effects in vascular calcification and cardiac ischemia diseases, described in preclinical and clinical studies. These effects can reduce calcium and tissue levels, the generation of radical proteins and CPK and assay levels for better methodological rigor.